Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Saved in:
Main Authors: | Arvin Pramudita (Author), Cleopas M Rumende (Author), Ardi Findyartini (Author) |
---|---|
Format: | Book |
Published: |
Interna Publishing,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018) -
Impact of combination antiretroviral therapy initiation on adherence to antituberculosis treatment
by: Marlene Knight, et al.
Published: (2015) -
Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
by: Moitra S, et al.
Published: (2015) -
The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis
by: Blomberg Bjørn, et al.
Published: (2001) -
ANTITUBERCULOSIS DRUG ALLERGY IN PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS
by: B.B. MAYKANAEV, et al.
Published: (2021)